Classification of Alzheimer’s Disease by Combination of Convolutional and Recurrent Neural Networks Using FDG-PET Images
Year: 2018
Type: article
Abstract: Alzheimer's disease (AD) is an irreversible brain degenerative disorder affecting people aged older than 65 years. Currently, there is no effective cure for AD, but its progression can be delayed with some treatments. Accurate and early diagnosis of AD is vital for the patient care and development of future treatment. Fluorodeoxyglucose positrons emission tomography (FDG-PET) is a functional molecular imaging modality, which proves to be powerful to help understand the anatomical and neural changes of brain related to AD. Most existing methods extract the handcrafted features from images, and then design a classifier to distinguish AD from other groups. These methods highly depends on the preprocessing of brain images, including image rigid registration and segmentation. Motivated by the success of deep learning in image classification, this paper proposes a new classification framework based on combination of 2D convolutional neural networks (CNN) and recurrent neural networks (RNNs), which learns the intra-slice and inter-slice features for classification after decomposition of the 3D PET image into a sequence of 2D slices. The 2D CNNs are built to capture the features of image slices while the gated recurrent unit (GRU) of RNN is cascaded to learn and integrate the inter-slice features for image classification. No rigid registration and segmentation are required for PET images. Our method is evaluated on the baseline FDG-PET images acquired from 339 subjects including 93 AD patients, 146 mild cognitive impairments (MCI) and 100 normal controls (NC) from Alzheimer's Disease Neuroimaging Initiative (ADNI) database. Experimental results show that the proposed method achieves an area under receiver operating characteristic curve (AUC) of 95.3% for AD vs. NC classification and 83.9% for MCI vs. NC classification, demonstrating the promising classification performance.
Source: Frontiers in Neuroinformatics
Authors: Manhua Liu, Danni Cheng, Weiwu Yan, Alzheimer’s Disease Neuroimaging Initiative
Institution: Shanghai Jiao Tong University
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,801
Funders: Foundation for the National Institutes of Health, Alzheimer's Association, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, GlaxoSmithKline, Novartis, F. Hoffmann-La Roche, Medpace, Synarc, Alzheimer's Disease Neuroimaging Initiative, Northern California Institute for Research and Education, National Natural Science Foundation of China, Elan, Eisai, Shanghai Jiao Tong University, National Institutes of Health, U.S. Food and Drug Administration, Genentech, University of California, Los Angeles, University of California, San Diego, National Key Research and Development Program of China, National Institute on Aging, National Institute of Biomedical Imaging and Bioengineering
OpenAlex ID: W2805773775
